Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced colorectal cancer failed from all standard chemotherapy~  * History of refractoriness from chemotherapy including 5-FU, Oxaliplatin, Irinotecan~ * Oral 5-FU agents are included standard chemotherapy~ * Targeted agents such as cetuximab or bevacizumab are not included in inclusion criteria~* Patient must have willingness and ability to comply with the study protocol including visiting hospital for test and treatment during trial~* ECOG performance status 0\~2~* Measurable lesion (RECIST 1.1) must exist~* Expected survival should be more than 3 months from first dose of pemetrexed~* Adequate organ function as defined as below estimated 28 days before first doe of pemetrexed:~Exclusion Criteria:~* Poor performance status (ECOG PS ≥ 3)~* Patient can not take folic acid or Vitamin B12.~* History of previous treatment with pemetrexed~* History of malignant disease, except: non-melanoma skin cancer that properly treated, cured uterine cervical cancer or other solid tumor without evidence of recurrence within 5 years~* Patient can not swallow oral pills.~* Treatment with medication of clinical trial within 14 days (or longer duration according to specific agents)~* Systemic chemotherapy or radiation (except palliative purpose) within 3 weeks (or longer duration according to specific agents)~* Toxicity from previous treatment as CTCAE grade \> 1, except alopecia~* bowel obstruction or CTCAE grade 3/4 upper GI bleeding before 4 weeks~* QTc prolongation (QTc \> 480msec) at resting is documented more than twice within 24 hours or family history of QT prolongation syndrome

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed+Tarceva (Type: EXPERIMENTAL): Pemetrexed 500 mg/m2 IV Q 3 weeks Tarceva 100mg once daily, continous

Based on this trial design, predict the completion outcome and termination type (if applicable).